Shorter versus longer corticosteroid duration and recurrent immune checkpoint inhibitor-associated AKI.
Shruti GuptaClara Garcia-CarroJason M ProsekIlya GlezermanSandra M HerrmannPablo GarciaAla AbudayyehNuttha LumlertgulA Bilal MalikSebastian LoewPazit BeckermanAmanda D RenaghanChristopher A CarlosArash RashidiZain MithaniPriya DeshpandeSunil RangarajanChintan V ShahSophie De SeigneuxLuca CampedelAbhijat KitchluDaniel Sanghoon ShinGaia CoppockDavid I Ortiz-MeloBen SprangersVikram AggarwalKarolina BenesovaRimda WanchooNaoka MurakamiFrank B CortazarKerry Lynn ReynoldsMeghan E SiseMaria José SolerDavid E Leafnull nullPublished in: Journal for immunotherapy of cancer (2022)
A shorter duration of corticosteroids (28 days or less) may be safe for patients with ICPi-AKI. However, the findings may be susceptible to unmeasured confounding and further research from randomized clinical trials is needed.
Keyphrases